IRIS
COVRE, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.504
EU - Europa 3.140
AS - Asia 1.964
SA - Sud America 312
Continente sconosciuto - Info sul continente non disponibili 222
AF - Africa 105
OC - Oceania 10
Totale 10.257
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.423
IT - Italia 885
RU - Federazione Russa 866
SG - Singapore 776
CN - Cina 463
IE - Irlanda 434
BR - Brasile 254
VN - Vietnam 254
GB - Regno Unito 243
FR - Francia 191
HK - Hong Kong 165
SE - Svezia 135
DE - Germania 110
UA - Ucraina 77
ZA - Sudafrica 74
BD - Bangladesh 72
FI - Finlandia 67
IN - India 61
KR - Corea 47
CA - Canada 45
ES - Italia 41
NL - Olanda 23
PL - Polonia 18
IQ - Iraq 17
MX - Messico 17
AR - Argentina 14
TR - Turchia 14
AT - Austria 13
EC - Ecuador 13
ID - Indonesia 10
JO - Giordania 10
AU - Australia 9
JP - Giappone 9
KE - Kenya 9
AL - Albania 7
AZ - Azerbaigian 7
CR - Costa Rica 7
PH - Filippine 7
CL - Cile 6
CO - Colombia 6
UY - Uruguay 6
LT - Lituania 5
MA - Marocco 5
NP - Nepal 5
SA - Arabia Saudita 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
DZ - Algeria 4
IL - Israele 4
PY - Paraguay 4
MY - Malesia 3
NO - Norvegia 3
PA - Panama 3
PE - Perù 3
PK - Pakistan 3
RO - Romania 3
AM - Armenia 2
CH - Svizzera 2
EG - Egitto 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
OM - Oman 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
UZ - Uzbekistan 2
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
LB - Libano 1
MD - Moldavia 1
MR - Mauritania 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
Totale 10.033
Salva come PNG Salva come JPEG
Città #
Dallas 741
Dublin 431
Singapore 431
Fairfield 407
Ashburn 338
San Jose 299
Moscow 248
Santa Clara 233
Milan 223
Woodbridge 184
Seattle 176
Hong Kong 159
Houston 159
Cambridge 158
Wilmington 154
Council Bluffs 150
Southend 150
Beijing 147
New York 102
Rome 82
Los Angeles 80
Hefei 79
Jacksonville 75
Princeton 73
Florence 72
Siena 72
The Dalles 72
Ho Chi Minh City 70
Johannesburg 70
Lauterbourg 68
Dong Ket 50
Helsinki 47
Ann Arbor 44
Seoul 44
Shanghai 44
Hanoi 43
San Mateo 38
San Diego 34
Chandler 30
Munich 27
Málaga 27
Dearborn 25
Stockholm 22
São Paulo 22
Redondo Beach 21
Borgo San Lorenzo 20
Buffalo 20
London 18
Chicago 17
Lappeenranta 16
Montreal 16
Orem 16
Phoenix 16
Chennai 15
Columbus 15
Denver 15
Fremont 15
Modena 14
Toronto 14
Atlanta 13
Frankfurt am Main 13
Naples 13
Nuremberg 13
Palermo 13
San Francisco 13
Sesto Fiorentino 13
Turin 13
Warsaw 13
Haiphong 12
Manchester 11
Poplar 11
Amsterdam 10
Empoli 10
Figino 10
Guangzhou 10
Vienna 10
Bengaluru 9
Guayaquil 9
Perugia 9
Rio de Janeiro 9
Tokyo 9
Amman 8
Boardman 8
Brooklyn 8
Da Nang 8
Piscataway 8
Portsmouth 8
Charlotte 7
Mexico City 7
Mumbai 7
Barnet 6
Cascina 6
Düsseldorf 6
Hangzhou 6
Lucca 6
Montevideo 6
Ninh Bình 6
Orbetello 6
Redwood City 6
Sydney 6
Totale 6.823
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 511
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 272
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 259
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 249
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 238
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 235
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 235
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 235
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 223
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 214
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 212
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 212
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 208
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 205
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 204
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 200
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 198
A novel microRNA signature for the detection of melanoma by liquid biopsy 195
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 192
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 190
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 189
Epigenetically-regulated Tumor-Associated Antigens in melanoma 189
Immunotherapy targeting immune check-point(s) in brain metastases 184
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 179
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 179
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 173
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 172
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 167
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 161
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 158
Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens 155
Challenges in lung cancer therapy during the COVID-19 pandemic 155
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 153
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 146
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients 145
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma 145
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status 140
Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. 140
COVID and Lung Cancer 139
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 139
Epigenetics meets immune checkpoints 138
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? 133
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 127
Epigenetic mechanisms in cancer formation and progression 124
The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology 122
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 120
Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy, 5:1103-1116, 2013 120
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 117
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 113
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 111
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets 106
Abstract 4841: DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 103
Clonal heritability of CTA expression and promoter methylation patterns in melanoma cells: Bases for epigenetic therapy? 101
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 97
Immunotherapy of brain metastases: breaking a "dogma" 95
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy 91
The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma 90
Whole genome methylation profiles and survival of melanoma patients 80
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer 72
Immunomodulatory activity of SGI-110, a secon generation hypometilating agent 70
Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma 68
Abstract 2632: A new paradigm for brain tumors treatment: Guadecitabine as a fundamental player to improve tumor immune response 65
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome 63
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study 36
Totale 10.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022447 0 61 42 10 8 30 20 19 31 58 63 105
2022/2023517 50 36 103 49 11 94 17 29 41 29 41 17
2023/2024753 31 19 71 27 22 215 235 26 27 9 24 47
2024/20251.516 58 42 133 88 205 99 40 86 191 81 163 330
2025/20264.667 251 405 686 523 976 183 469 166 148 249 199 412
2026/2027374 254 120 0 0 0 0 0 0 0 0 0 0
Totale 10.257